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Summary
We show that integrin-linked kinase (ILK) stimulates the expression of VEGF by stimulating HIF-1 protein expression in
a PKB/Akt- and mTOR/FRAP-dependent manner. In human prostate cancer cells, knockdown of ILK expression with siRNA,
or inhibition of ILK activity, results in significant inhibition of HIF-1 and VEGF expression. In endothelial cells, VEGF
stimulates ILK activity, and inhibition of ILK expression or activity results in the inhibition of VEGF-mediated endothelial
cell migration, capillary formation in vitro, and angiogenesis in vivo. Inhibition of ILK activity also inhibits prostate tumor
angiogenesis and suppresses tumor growth. These data demonstrate an important and essential role of ILK in two key
aspects of tumor angiogenesis: VEGF expression by tumor cells and VEGF-stimulated blood vessel formation.
Introduction mutations in PI-3 kinase or its downstream effector, PKB/Akt, or
by the mutational inactivation, or loss of the tumor suppressor,
PTEN (Cantley and Neel, 1999). The constitutive upregulationAngiogenesis plays a critical role in cancer progression (Hana-
han and Weinberg, 2000). Tumor growth and metastasis have of expression of VEGF by tumor cells is felt to be a major
contributor to tumor angiogenesis (Ferrara, 2002).been shown to be dependent on angiogenesis, and inhibition of
tumor angiogenesis by selectively inhibiting the growth, survival, VEGF expression is regulated at the level of transcription
by a variety of transcription factors that include AP-1, NF-B,and migration of endothelial cells is perceived as an attractive,
nontoxic means of regulating tumor progression (Kerbel, 1991). and hypoxia-inducible factor-1 (HIF-1) (Huang et al., 2000;
Ryan et al., 1998; Damert et al., 1997). The major physiologicalA variety of proteins have been identified as potential targets
of antiangiogenesis therapy, and despite poor results in clinical stimulus for VEGF expression is hypoxia, resulting in the tran-
scriptional induction of the VEGF gene by HIF-1 (Forsythe ettrials of some of the antiangiogenic strategies (Kerbel and Folk-
man, 2002), the potential of antiangiogenic therapy continues al., 1996; Carmeliet et al., 1998; Ryan et al., 1998), which is
a heterodimeric transcription factor composed of HIF-1 andto be an attractive means of cancer control.
One of the key mediators of angiogenesis is vascular endo- HIF-1 subunits (Jiang et al., 1996). The hypoxia-mediated stim-
ulation of HIF-1 expression is regulated by the inhibition ofthelial cell growth factor (VEGF), which can promote the prolifer-
ation, survival, and migration of endothelial cells and is essential ubiquitin-mediated degradation and consequent stabilization of
the HIF-1 subunit under hypoxic conditions. As a result, HIF-for blood vessel formation (Ferrara, 2002). VEGF is expressed
by activated endothelial cells, but more importantly for tumor 1 accumulates, dimerizes with HIF-1, and activates transcrip-
tion of target genes, including VEGF (reviewed in Harris, 2002).angiogenesis, VEGF expression and secretion are stimulated in
tumor cells by activation of oncogenes such as Ras (Rak et al., Recently, however, the expression of VEGF via the activation
of the PI-3 kinase pathway has also been shown to be mediated2000), as well as by the activation of the PI-3 kinase pathway
(Jiang et al., 2001; Fukuda et al., 2002), which has inherent by HIF-1 (Jiang et al., 2001; Fukuda et al., 2002). Signaling
via receptor tyrosine kinases induces HIF-1 expression by anoncogenic properties. The PI-3 kinase pathway can be constitu-
tively activated via autocrine growth factors by constitutively independent mechanism involving the stimulation of increased
rates of HIF-1 protein synthesis via PI-3 kinase-dependentactivated growth factor receptors such as Erb-B2, by activating
S I G N I F I C A N C E
Constitutive activation of the PI-3 kinase pathway is oncogenic and is implicated in the promotion of tumor angiogenesis by stimulating
the expression of VEGF. The integrin-linked kinase (ILK) is a PI-3 kinase-dependent effector of integrin-mediated cell adhesion as
well as growth factors and is an upstream regulator of PKB/Akt. Here we show that ILK is essential for HIF-1 and VEGF expression
in prostate cancer cells and that it is also essential for VEGF-stimulated endothelial cell migration, tube formation, and tumor
angiogenesis. Consequently, ILK plays important roles in two key aspects of tumor angiogenesis: VEGF expression by tumor cells
and VEGF-stimulated blood vessel formation. Our findings suggest that ILK is a promising therapeutic target for the inhibition of tumor
angiogenesis.
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stimulation of PKB/Akt and mTOR/FRAP, which activates the
translational regulatory protein eIF-4E binding protein 1 (4E-
BP1) and p70 S6 kinase (Fukuda et al., 2002; Laughner et al.,
2001; Gingras et al., 2001; Peterson et al., 1999). These findings
indicate that HIF-1 regulates both hypoxia- and growth factor-
induced VEGF expression.
One of the components of the PI-3 kinase pathway, immedi-
ately upstream of PKB/Akt, is integrin-linked kinase (ILK) (Hanni-
gan et al., 1996; Wu and Dedhar, 2001; Troussard et al., 2003).
ILK can interact with the cytoplasmic domain of -integrin sub-
units and is activated by both integrin activation as well as
growth factors (Wu and Dedhar, 2001). ILK is a PI-3 kinase-
dependent kinase (Persad et al., 2001a; Delcommenne et al.,
1998) and is an upstream regulator of the phosphorylation of
PKB/Akt on serine 473 (Troussard et al., 2003; Persad et al.,
2000, 2001a; Lynch et al., 1999; Delcommenne et al., 1998), one
of the two phosphorylation sites required for the full activation of
PKB/Akt. Overexpression of ILK induces anchorage-indepen-
dent cell growth and suppression of anoikis and promotes hy-
perplasia and tumor formation in vivo (Wu and Dedhar, 2001).
ILK activity is also constitutively activated in PTEN null cancer
cells, and the constitutive activation of PKB/Akt in such cells is
inhibited upon inhibition of ILK activity (Persad et al., 2000). ILK
also promotes cell migration and invasion (Persad and Dedhar,
2003). Because of these oncogenic properties of ILK, we de-
cided to explore the potential role of ILK in promoting tumor
angiogenesis. We wanted to determine whether ILK is involved
in the stimulation of expression of VEGF in tumor cells and
secondly whether ILK is required for VEGF-mediated endothelial
cell migration and formation of blood vessels.
In this paper, we report that overexpression of ILK stimulates
VEGF expression in a PKB/Akt- and HIF-1-dependent manner
and that inhibition of ILK expression or activity in VEGF-express-
ing prostate cancer cells (DU145 and PC3) results in dramatic
Figure 1. VEGF expression and HIF-1 activity are increased in epithelial cellsinhibition of VEGF expression and secretion via inhibition of
with a high ILK activity
PKB/Akt activity and HIF-1 expression. Furthermore, inhibition
A: Immunoblot analysis with the indicated antibodies of NP-40 cell lysatesof ILK activity or expression in VEGF-stimulated endothelial cells
of the indicated cell lines transfected with 3 g HRE:GFP and pRenilla (trans-
results in the inhibition of endothelial cell migration and blood fection efficiency control) and exposed (24 hr) to 1% FBS media.
vessel formation in vitro and in vivo. A small molecule ILK inhibi- B: Immunoblot analysis with the indicated antibodies of the RIPA IEC-18 ILK
13 A1a3 cell lysates 4 days posttransfection with the indicated type andtor suppresses tumor angiogenesis and tumor growth in a PC3
amount of siRNA. All figures are a representation of three trials.xenograft tumor model. Our results demonstrate an important
and essential role of ILK in two key aspects of tumor angiogen-
esis, VEGF expression by tumor cells and VEGF-stimulated
blood vessel formation, and suggest that ILK may be a promising
pression also resulted in the stimulation of VEGF expression.therapeutic target for the inhibition of tumor angiogenesis.
As shown in Figure 1A, the expression of both isoforms of VEGF
is markedly stimulated in the ILK-overexpressing clone of IEC-Results
18 cells (ILK-13, A1a3), as compared to control clones express-
ing the E359K kinase-deficient ILK dominant-negative (ILK-DN,Overexpression of ILK stimulates VEGF expression
GH31RH) or antisense-ILK (ILK-14) (Novak et al., 1998; Hanni-in a PKB/Akt- and HIF-1-dependent manner
gan et al., 1996). In addition, the data in Figure 1A also showWe have previously demonstrated that overexpression of ILK
markedly increased phosphorylation of PKB/Akt on serine 473in IEC-18 rat intestinal epithelial cells results in anchorage-inde-
in the absence of any changes in PKB/Akt expression. Sincependent cell cycle progression, tumorigenicity in nude mice,
one of the major transcriptional regulators of the VEGF gene isactivation of PKB/Akt, inhibition of GSK-3, and stimulation of
hypoxia-inducible factor-1 (HIF-1), we transfected the differ-AP-1, NF-B, and -catenin/LEF transcription factors (reviewed
ent IEC-18 clones described above with a HIF-1 response ele-in Wu and Dedhar, 2001). Overexpression of a kinase-deficient
ment fused to a green fluorescence protein (GFP) reportermutant of ILK, or ILK antisense cDNA, did not result in the
(HRE:GFP) (Ruan and Deen, 2001). As shown in Figure 1A, thisstimulation of these pathways or phenotypes. Because activa-
reporter is only active in the ILK-overexpressing clone, sug-tion of other oncogenes such as Ras or the PI-3 kinase pathway
gesting that the stimulation of VEGF expression in these cellshas been shown to stimulate VEGF expression in tumor cells
(Rak et al., 2000), we wanted to determine whether ILK overex- is likely mediated by the upregulation or activation of the HIF-1
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transcription factor. We were unable to directly analyze HIF-1
protein expression in these clones because of the lack of avail-
ability of suitable anti-rat HIF-1 antibodies. Inhibition of ILK
expression in the A1a3 ILK overexpressing cells with ILK siRNA
resulted in the suppression of VEGF expression (Figure 1B),
showing that ILK is indeed responsible for the stimulation of
VEGF expression in these cells. We have previously shown
that the ILK-overexpressing clones have constitutive high-level
expression of cyclin D1 (Radeva et al., 1997), and inhibition of
ILK expression by siRNA inhibits cyclin D1 expression (Trous-
sard et al., 2003). As shown in Figure 1B, ILK siRNA also results
in the suppression of cyclin D1 expression in the ILK-overex-
pressing cells. These data demonstrate that overexpression of
kinase-active ILK results in the stimulation of VEGF expression
via the activation of PKB/Akt and the HIF-1 transcription factor.
Inhibition of ILK expression and activation suppresses
PKB/Akt and mTOR/FRAP phosphorylation and inhibits
HIF-1 and VEGF expression in prostate cancer cells
In order to analyze in more detail the ILK-mediated signaling
pathway leading to the stimulation of VEGF and to assess the
relevance of ILK in VEGF expression in cancer cells, we decided
to inactivate ILK expression or activity in human prostate cancer
cells that express VEGF.
The PI-3 kinase pathway is constitutively activated in many
cancer cells lines. In certain human prostate cancer cell lines
(PC3 and LnCAP), the PI-3 kinase pathway is constitutively
activated due to the loss of expression of the tumor suppressor
PTEN (Davies et al., 1999; Stambolic et al., 1998). We have
previously shown that ILK activity is also constitutively activated
in these cells and that inhibition of ILK activity suppresses PKB/
Akt activity in these PTEN null cells (Persad et al., 2000). VEGF
expression has been shown to be constitutively elevated in
PC3 cells (Jiang et al., 2001). Because we had found that ILK
stimulated VEGF expression (Figure 1), we wanted to determine
whether inhibition of ILK activity in PC3 cells resulted in the
inhibition of VEGF expression. As shown in Figure 2A, inhibition
of ILK activity by transfection of kinase-deficient, ILK-DN
(E359K) (Persad et al., 2000), or wild-type PTEN resulted in
inhibition of VEGF expression at the protein level as determined
by Western blotting. In addition, the expression of HIF-1 pro-
tein is also substantially inhibited by DN-ILK and PTEN (Figure
2A). As expected, DN-ILK also inhibited phosphorylation of
PKB/Akt on serine 473 (Figure 2A). Expression of dominant-
negative ILK and PTEN also inhibited the activity of the HIF-1
response element (HRE), as shown in Figure 2C, suggesting
that the upregulation of VEGF expression in these cells is likely
due to the ILK-mediated upregulation of HIF-1 expression.
Figure 2. VEGF and HIF-1 expression are severely affected by the loss of ILKWe have recently utilized double-stranded RNA interference
activity in a PTEN- and mTOR/FRAP-dependent manner in PTEN null prostate(siRNA) to knock down ILK protein expression (Troussard et al.,
carcinoma cells (PC3)2003). Furthermore, we have shown that ILK knockdown by
A: Immunoblot analysis with the indicated antibodies of the RIPA lysate ofsiRNA results in significant inhibition of PKB/Akt serine 473
PC3 cells transfected with 1–2g of Empty:V5, ILK-DN:V5 or PTEN:GFP vector.
phosphorylation and activation (Troussard et al., 2003). We B: Immunoblot analysis with the indicated antibodies of the RIPA lysate of
therefore exposed PC3 cells to increasing concentrations of PC3 cells transfected with the indicated type and amount of siRNA.
C: Immunoblot analysis with the indicated antibodies of NP-40 lysate of PC3ILK-specific siRNA (Troussard et al., 2003). As shown in Figure
cells cotransfected with the indicated constructs and pRenilla after 48 hr.2B, ILK siRNA resulted in the complete depletion of ILK expres-
All figures are a representation of three trials.sion in PC3 cells. This was associated with a suppression of
phosphorylation of PKB/Akt on serine 473. Expression of PKB/
Akt was not affected (Figure 2B). Furthermore, ILK siRNA-medi-
ated knockdown of ILK also resulted in significant inhibition of
expression of both HIF-1 and VEGF protein (Figure 2B). It has
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been recently shown that PKB/Akt can regulate the expression
of HIF-1 protein at the translational level by stimulating the
phosphorylation of mTOR/FRAP, which is a regulator of protein
synthesis (Gingras et al., 2001; Peterson et al., 1999). We there-
fore wanted to determine whether the ILK-mediated expression
of HIF-1 and VEGF also involved mTOR/FRAP. As shown in
Figure 2B, siRNA-mediated knockdown of ILK resulted in the
inhibition of mTOR/FRAP phosphorylation on serine 2448, con-
comitant with the inhibition of the PKB/Akt phosphorylation.
The expression of mTOR/FRAP protein was not affected by the
knockdown of ILK. These data suggest that in the PC3 cells,
the constitutive activation of ILK drives VEGF expression most
likely via HIF-1 through the activation of PKB/Akt and mTOR/
FRAP, resulting in increased translation of HIF-1 protein. This
is further substantiated by the observation that transfection of
a dominant-negative HIF-1 construct into PC3 cells almost
completely inhibits VEGF expression as well as HRE activity
(Figure 2C).
Pharmacological inhibition of ILK activity results
in the inhibition of HIF-1 and VEGF expression
in prostate cancer cells
We have identified highly selective small molecule inhibitors of
ILK activity. These ATP competitive inhibitors have been exten-
sively characterized, and shown to inhibit ILK activity and the
activation of all of the downstream effectors of ILK (Cruet-Hen-
nequart et al., 2003; Mills et al., 2003; Persad et al., 2000, 2001a,
2001b; Tan et al., 2001, 2002; Troussard et al., 2000). The
inhibitors are equally effective and specific as ILK inhibition by
dominant-negative ILK and ILK siRNA (Persad et al., 2001a,
2001b; Troussard et al., 2003). We therefore wanted to deter-
mine whether exposure of human prostate cancer cells to the
ILK inhibitor would also inhibit the expression of HIF-1 and
the expression and synthesis of VEGF. As shown in Figure 3A,
exposure of both PC3 and DU145 prostate cancer cells to the
ILK inhibitor KP-392 (Persad et al., 2001a, 2001b) resulted in
the inhibition of both HIF-1 and VEGF expression in a dose-
Figure 3. Inhibition of ILK activity results in decrease of HIF-1 and VEGFdependent manner. Despite poor cellular permeability of this
expression in a PI-3 kinase-dependent manner in prostate carcinoma cellsinhibitor, resulting in the exposure of cells to relatively high
A: Immunoblot analysis with the indicated antibodies of RIPA lysate of PC3concentrations, it can be seen that there is significant inhibition
and DU145 cells starved (20 hr) and then exposed (24 hr) to the indicated
of both HIF-1 and VEGF expression at 25 M KP-392, espe- amounts of KP-392, equivalent amounts of DMSO vehicle, and 1% FBS.
cially in PC3 cells As well, it can clearly be seen that KP-392 B: Quantification by ELISA of the level of secreted VEGF protein in condi-
tioned media.also suppresses the phosphorylation of PKB/Akt on serine 473
C: Immunoblot analysis of RIPA lysates of DU145 cells cultured under thein a dose-dependent manner. Again, there is no effect on the
indicated conditions (24 hr). All figures are a representation of three trials.expression of PKB/Akt. In addition, as shown in Figure 3B,
not only VEGF cellular expression but also its secretion, as
determined by an enzyme-linked immunosorbant assay (ELISA)
of the conditioned cell media, are inhibited by the ILK inhibitor can result in substantial inhibition of the expression of both
KP-392. In contrast to PC3 cells, VEGF expression is not com- HIF-1 and VEGF, suggesting that ILK may be an important
pletely inhibited by the ILK inhibitor in DU145 cells, despite therapeutic target for the inhibition of expression of the angio-
substantial inhibition of HIF-1 expression. This suggests cell genic factor, VEGF.
type differences in the regulation of VEGF expression.
In Figure 3C, we demonstrate that HIF-1 expression is ILK regulates VEGF-mediated endothelial cell
stimulated by serum in serum-starved PC3 cells and that inhibi- migration and blood vessel formation
tion of ILK as well as PI-3 kinase with the respective pharma- VEGF stimulates endothelial cell survival and migration and pro-
cological inhibitors KP-392 and LY294002 inhibits HIF-1 ex- motes the formation of new blood vessels (Ferrara, 2002). Since
pression. the activity of ILK is stimulated by various growth factors and
Collectively, the data shown in Figures 2 and 3 demonstrate chemokines (Wu and Dedhar, 2001; Friedrich et al., 2002) and
that ILK is a critical component of the constitutively activated ILK also promotes cell migration and invasion (Persad and Ded-
PI-3 kinase-PKB/Akt signaling pathway resulting in the stimula- har, 2003), we wanted to determine whether ILK also played a
role in VEGF-mediated endothelial cell migration and vasculartion of HIF-1 and VEGF. Inhibition of ILK expression or activity
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Figure 4. ILK kinase activity is involved in VEGF-stimulated HUVEC activity
A: ILK kinase activity is stimulated by VEGF in HUVEC. Cells were starved (24 hr) and exposed to the indicated amounts of VEGF and LY294002. The ILK
kinase assay was carried out as described in the Experimental Procedures. This is a representation of three independent trials.
B: Decrease in ILK activity reduces HUVEC invasion and migration toward VEGF. Two hours after HUVEC were seeded on the upper chamber, indicated
amounts of KP-392 were added to this chamber, and the migration assay was performed and analyzed as described in Experimental Procedures. This
graph represents the mean of three experiments  SD.
C: Knockdown of ILK expression reduces HUVEC invasion and migration toward VEGF. Equal number of HUVEC transfected for 3 days with the indicated
siRNA (25 nM) were seeded in the upper chamber. The experiment was performed as described in Experimental Procedures. This graph represents the
mean of three experiments  SD.
D: Immunoblot analysis with the indicated antibodies of RIPA lysate of transfected HUVEC (25 nM indicated siRNA) that were starved (24 hr) then exposed
(24 hr) to VEGF (0 or 20 ng/ml) 2 days posttransfection. The graph represents relative HUVEC growth after above conditions, measured by WST-1/ECS assay.
Results represent mean absorbance  SD. This is a representation of three experiments.
morphogenesis. As shown in Figure 4A, VEGF stimulates ILK VEGF-mediated HUVEC cell migration. Furthermore, inhibition
of ILK expression in HUVEC cells by ILK siRNA also inhibitedkinase activity in a dose-dependent manner in quiescent human
umbilical vein endothelial cells (HUVEC). The stimulation of ILK VEGF-stimulated HUVEC cell migration (Figure 4C), demonstra-
ting an essential role for ILK in the stimulation of endothelialactivity by VEGF is dependent on PI-3 kinase activity since the
VEGF stimulation of ILK activity is inhibited in the presence of the cell migration by VEGF. We also noted inhibition of cyclin D1
expression in the ILK siRNA transfected HUVEC cells (FigurePI-3 kinase inhibitor, LY294002. These data support previous
studies showing ILK to be a PI-3 kinase-dependent kinase (Del- 4D), indicating that inhibiting ILK may also inhibit VEGF-stimu-
lated HUVEC cell proliferation. As shown in Figure 4D, HUVECcommenne et al., 1998; Lynch et al., 1999) and demonstrate
that VEGF stimulates ILK activity in a PI-3 kinase-dependent cell proliferation in response to VEGF is inhibited in the ILK
siRNA transfected cells. Cell viability in the ILK siRNA trans-manner. We next determined whether ILK was required for the
stimulation of VEGF-mediated cell migration of HUVEC cells. fected cells was not significantly altered (data not shown). These
data demonstrate an essential role of ILK in VEGF–mediatedAs shown in Figure 4B, VEGF stimulates the migration of HUVEC
cells, and inhibition of ILK activity with the pharmacological HUVEC cell migration and proliferation. It has been demon-
strated that VEGF promotes its own expression in endothelialILK inhibitor, KP-392, results in a dose-dependent inhibition of
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Figure 5. KP-392 inhibits angiogenesis in matrigel and in vivo
A: HUVEC-coated beads embedded in fibrin were incubated in the indicated conditions (VEGF [0 or 20 ng/ml]; KP-392 [M]). Micrographs of a typical
bead were taken at 72 hr. Number of capillary-like tubes formed per microcarrier bead (sprouts/bead) were counted and analyzed as described in
Experimental Procedures. The graph represents the mean of three experiments  SD. The graph below represents relative cell viability after exposure (24
hr) to the indicated amounts of KP-392, LY294002, and VEGF, measured by WST-1/ECS assay. Results represent mean absorbance  SD.
B: HUVEC suspension in Matrigel were incubated with VEGF and DMSO (Control) or 50 M KP-392. Micrographs of a typical field were taken to illustrate
HUVEC tube formation.
C: Photographs of developing chick chorioallantoic membranes incubated with 30 ng/ml VEGF and DMSO (Control) or 50 M KP-392. Dashed circle
outlines the area covered by the gelatin sponges. Arrows show blood vessels migrating away from the area containing KP-392. All figures are a representation
of three independent experiments.
cells via a positive autocrine loop involving HIF-1 expression mental Procedures. Both the KP-392 ILK inhibitor and the PI-3
kinase inhibitor LY294002 inhibited cell sprouting. Exposure ofand activity (Stoeltzing et al., 2003; Zhong et al., 2000). It is there-
fore interesting to note that VEGF-stimulated HIF-1 expression cells to 50 M KP-392 and 20 M LY294002 completely inhib-
ited VEGF-induced HUVEC sprouting. In contrast, the MEK in-in HUVEC cells is inhibited by ILK siRNA (Figure 4D), suggesting
that ILK is a component of this positive feedback loop. hibitor, PD98059, did not have any significant inhibitory effect
in this assay. The ILK inhibitor had only minor effects on HUVECWe next wanted to determine whether ILK is required for
VEGF-mediated blood vessel formation. To evaluate this, we cell viability, and only at very high concentrations (Figure 5A).
These data demonstrate that PI-3 kinase and ILK activities areinitially utilized an in vitro endothelial cell sprouting assay. As
shown in Figure 5A, VEGF significantly stimulated HUVEC capil- required for VEGF-mediated vascular morphogenesis in vitro.
Another assay that is frequently used for the demonstrationlary sprouting, which was quantified as described in the Experi-
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function in response to VEGF, suggesting an essential role of
ILK in blood vessel formation.
Inhibition of ILK activity inhibits VEGF-stimulated
angiogenesis in vivo
We next wanted to determine whether inhibiting ILK activity
resulted in the inhibition of VEGF-stimulated angiogenesis in
vivo. We utilized a well-established assay for angiogenesis, the
chicken chorioallantoic membrane (CAM) assay (Auerbach et
al., 1975), to determine the effects of the ILK inhibitor, KP-392.
As shown in Figure 5C, inhibition of ILK activity had a significant
effect on VEGF-stimulated blood vessel formation in vivo. In
the CAM assay (Figure 5C), the incorporation of KP-392, com-
pared to vehicle alone, together with VEGF resulted in the com-
plete blockage of growth of blood vessels toward VEGF. It is
interesting to note that the blood vessels are not lysed in the
presence of KP-392, but rather they fail to grow toward VEGF
and seem to be repelled away from VEGF, demonstrating that
the inhibition of ILK predominantly inhibits the migration of endo-
thelial cells and blood vessels toward VEGF.
Inhibition of tumor angiogenesis and suppression
of tumor growth in ILK inhibitor-treated PC3
xenograft tumor model
The data presented above suggest that inhibition of ILK activity
or expression should inhibit tumor angiogenesis and if PC3
tumor growth in vivo is dependent on tumor vascularization,
then ILK inhibition should also induce tumor growth inhibition.
To determine whether inhibition of ILK affected tumor angiogen-
esis and tumor growth in vivo, we established PC3 tumors in
nude mice (Figure 6) and treated mice with established tumors
with the ILK inhibitor KP-307-2, an analog of KP-392. As shown
in Figure 6A, there was a statistically significant effect on tumor
vascularization as determined by microvessel density in anti-
CD31 stained KP-307-2 treated and control tumor sections. In
Figure 6. Inhibition of ILK activity suppresses tumor angiogenesis and tumor addition, there was statistically significant tumor growth sup-
growth rate pression in the ILK inhibitor-treated mice over a 28 day dosing
Nude mice with PC3 flank tumors were treated with daily i.p. injection of regimen (Figure 6B). The inhibitor was well tolerated with no
100 mg/kg ILK inhibitor or vehicle for 28 days.
obvious side effects or weight loss (data not shown). TheseA: 7 days after dosing, one tumor from each mouse was harvested and
data indicate that ILK is a mediator of prostate tumor angiogen-tumor vascular density was analyzed as described in Experimental Proce-
dures. The bar graph shows the means of neovascular densities/field for esis, and therefore a target for antiangiogenic therapy.
each group  SD. Shown are representative photographs of neovascula-
ture in the PC3 tumors. Discussion
B: Relative change in tumor volumes in eight mice in the control group and
ten mice in the treatment group  SEM. **: p  0.01; *: p  0.05.
Angiogenesis is important in cancer progression and is one of
the hallmarks of tumor metastasis (Hanahan and Weinberg,
2000). A principal mediator of tumor angiogenesis is VEGF and
a major transcriptional activator of the VEGF gene is HIF-1of angiogenesis in vitro is the endothelial tube formation assay
(Harris, 2002). It has been reported that the PI-3 kinase/Aktin which endothelial cells placed on matrigel in the presence of
signaling pathway mediates angiogenesis and the expressionangiogenic factors results in the endothelial cells forming tube-
of VEGF in cells by elevating the levels of HIF-1 protein in
like structures morphologically similar to capillaries. This tube
cells independent of hypoxic condition (Semenza, 2002). This
formation represents the contribution of cell survival, migration, hypoxia-independent stimulation of HIF-1 and VEGF in cancer
and proliferation (Folkman and Haudenschild, 1980). As shown cells can be mediated by autocrine or chronic stimulation by
in Figure 5B, HUVEC cells cultured on matrigel in the presence growth factors such as IGF-1, constitutive activation of PI-3
of VEGF formed tube structures that were completely inhibited kinase, or the constitutive activation of PKB/Akt due to the
by the ILK inhibitor, KP-392. At the same KP-392 concentra- inactivation of the tumor suppressor, PTEN (Brazil et al., 2002;
tions, significant inhibition of HUVEC cell migration and capillary Galetic et al., 1999). Because ILK is PI-3 kinase dependent and
sprout formation were observed (Figures 4B and 5A). an upstream target of Akt/PKB and because an increase in
These three different in vitro assays demonstrate that the ILK expression is positively correlated with prostate carcinoma
grade (Graff et al., 2001), ILK was a likely candidate to be in-inhibition of ILK activity has a dramatic effect on endothelial cell
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Figure 7. Schematic representation of the cell
signaling events leading to VEGF production in a
prostate carcinoma cell and consequent effects
on a neighboring endothelial cell
Shown is our model for the production of VEGF
in prostate carcinoma cell and the effects of
VEGF on endothelial cell function. Phosphoryla-
tion of serine 473 of Akt/PKB by activated ILK in
prostate cancer cells results in the full activation
of PKB/Akt that promotes the phosphorylation of
serine 2448 of mTOR/FRAP. This activates mTOR/
FRAP, which increases the levels of HIF-1 protein
translation. HIF-1 protein combines with HIF-1
to form an active transcription factor. This hetero-
dimer binds to the VEGF promoter and activates
VEGF transcription, expression, and secretion.
VEGF binds to its receptor on nearby endothelial
cells and stimulates ILK activity. ILK regulates
downstream targets involved in cell survival, pro-
liferation, invasion migration, and sprout forma-
tion, which result in angiogenesis toward the
VEGF gradient.
volved in the regulation of VEGF and HIF-1 expression through (Scandurro et al., 2001; Grimshaw and Mason, 2001), sug-
gesting that ILK may also play a role in hypoxia-induced VEGFAkt/PKB activity regulation. In addition, the regulation of HIF-1
translational rate has been shown to be through the regulation of expression. Thus, the role of ILK in hypoxic tumors with constitu-
tive activation of PI-3 kinase may be quite substantial.mTOR/FRAP, a downstream target of Akt/PKB (Fukuda et al.,
2002). We have also shown here that ILK plays an essential role
in VEGF-stimulated endothelial cell-mediated blood vessel for-In this paper, we have shown that in human prostate cancer
cells, ILK is essential for the regulation of HIF-1 expression mation in vitro and in vivo (Figure 6). Migration and proliferation
of human endothelial cells in response to VEGF are inhibitedand the consequent production of VEGF. Functional inactivation
of ILK by exposure to a highly selective chemical inhibitor, or upon inhibition of ILK activity or expression. Furthermore, the
ability of VEGF-stimulated endothelial cells to form capillary-stable or transient transfection of the ILK dominant-negative
construct into cell models with high ILK activity, result in a like structures in vitro is also severely inhibited by inhibiting ILK
activity. This inhibition appears to be due primarily to inhibitiondecrease in HIF-1protein levels and VEGF expression. Further-
more, depletion of ILK protein by siRNA in PC3 cells effectively of cell migration and proliferation, both of which can be regu-
lated by ILK in response to growth factors or engagement ofdecreases Akt/PKB and mTOR/FRAP phosphorylation, HIF-1
levels, and VEGF expression. These data suggest that in certain integrins (Wu and Dedhar, 2001; Cruet-Hennequart et al., 2003).
The inhibition of angiogenesis in vivo in the CAM assay bycancer cells, such as prostate carcinoma cells, ILK plays a
crucial role in HIF-1 and VEGF expression via activation of inhibition of ILK suggests that the primary effect of ILK inhibition
is on endothelial cell migration and ability to form vessels, asPKB/Akt and phosphorylation of mTOR/FRAP (Figure 7). VEGF
gene transcription can also be stimulated by the transcription there did not appear to be any obvious cell lysis in these assays.
This agrees with our finding that HUVEC cell survival appearsfactors AP-1 and NF-B (Harris, 2002). Since ILK has also been
shown to regulate the activities of both of these transcription not to be affected as significantly as cell migration and prolifera-
tion upon ILK inhibition. Recent evidence from the systemic andfactors (Troussard et al., 2000; Tan et al., 2002), it is possible
that in certain cell types ILK could regulate VEGF expression targeted knockout of ILK suggests an important role of ILK
in cell adhesion and actin accumulation (Sakai et al., 2003),via signaling pathways that activate these other transcription
factors. Although in this study we have not ruled out the contri- processes crucial for cell morphogenesis and migration, as well
as in cell proliferation (Terpstra et al., 2003).bution of AP-1 and NF-B in the ILK-mediated regulation of
VEGF expression in the prostate cancer cell lines examined, We have also shown here that inhibition of ILK with a highly
selective ILK inhibitor results in the statistically significant sup-the data presented here support a significant role of HIF-1 in
the ILK regulation of VEGF expression. This is particularly true pression of tumor angiogenesis as well as tumor growth in a
mouse xenograft model of PC3 tumor growth in SCID mice.for the PC3 cells in which inhibition of ILK expression or activity
results in almost complete suppression of both HIF-1 and These data suggest that inhibitors of ILK activity may be consid-
ered as angiogenesis inhibitors effective for the suppression ofVEGF expression. Furthermore, in the PTEN null PC3 cells in
which the PI-3 kinase pathway and ILK are constitutively upreg- tumor angiogenesis.
The integrins V3, V5, and 51 have also been shown toulated, transfection of dominant-negative HIF-1 results in sub-
stantial inhibition of VEGF expression. It is interesting to note be crucial regulators of endothelial cell function during angio-
genesis (Hood and Cheresh, 2002; Eliceiri and Cheresh, 2001;that ILK mRNA has been shown to be upregulated by hypoxia
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Western blottingFriedlander et al., 1995). Furthermore, angiogenesis inhibitors
Cell lyses and Western blotting were carried out as previously described bysuch as endostatin and tumstatin have been shown to function
us (Troussard et al., 2003; Cruet-Hennequart et al., 2003; Tan et al., 2001;by inhibiting integrin function and signaling (Maeshima et al.,
Persad et al., 2001a, 2001b). The following antibodies were used in this study:
2002). Tumstatin has been shown to inhibit endothelial cell sur- anti-phosphoserine 473 PKB/Akt, anti-PKB/Akt, and anti-phosphoserine
vival by binding to V3 and inhibiting V3-metiated signaling 21/9-glycogen synthase kinase-3 (GSK-3) antibodies from New England
to PKB/Akt (Maeshima et al., 2002). Since ILK is also regulated Biolabs, anti-V5 antibody from Invitrogen, anti-ILK and anti-HIF-1 antibod-
ies from BD Transduction, anti-phosphoserine 2448-mTOR/FRAP and anti-by integrins and since ILK is involved in V3-regualed cell prolif-
mTOR/FRAP antibodies from Cell Signaling, anti-VEGF antibody from Onco-eration (Cruet-Hennequart et al., 2003), as well as in regulating
gene Research Products, anti-green fluorescent protein (GFP) antibody fromanoikis (Attwell et al., 2000), it is likely that ILK also plays an
Boehringer Mannheim, and anti-mouse and anti-rabbit antibodies conju-
important role in integrin-mediated endothelial cell function dur- gated to horseradish peroxidase from Jackson Laboratories.
ing angiogenesis. We have recently created transgenic mice in
which the ILK gene is flanked by Lox-P sites and have demon- Quantification of VEGF in conditioned media
Secreted VEGF was quantified by using an enzyme linked immunoassaystrated that cells from these mice can be used to conditionally
(ELISA) kit for human VEGF (Oncogene Research Products) according toknockout ILK expression in cells isolated from these mice
the manufacturer’s instructions.(Troussard et al., 2003). The conditional knockout of ILK in
endothelial cells will provide further data on the precise mecha-
ILK kinase assay
nism of ILK function in endothelial cells. HUVECs were starved for 24 hr prior to the experiment. The cells were
The data shown in this paper demonstrate the importance exposed to increasing amounts of VEGF for 1 or 24 hr, followed by lysis
of ILK in the orchestration of tumor angiogenesis by regulating with NP-40 lysis buffer. Equivalent amounts (250 g) of lysate were immuno-
precipitated overnight with 3 mg of mouse monoclonal anti-ILK antibodyVEGF expression by carcinoma cells and VEGF-stimulated
(Upstate Biotechnologies Institute) at 4C. The immune complexes wereblood vessel formation. ILK occupies a pivotal position in regu-
isolated with protein A/G plus agarose beads (Santa Cruz Biotechnology)lating cell adhesion, actin polymerization, and signaling. A more
and washed three times with NP-40 lysis buffer and three times with last
detailed understanding of these processes is therefore of impor- wash buffer (50 mM HEPES [pH 7], 2 mM MgCl2, 2 mM MnCl2, 200 mM
tance for therapeutic intervention of tumor angiogenesis. Na3VO4, protease inhibitors). The kinase assay was performed using 2 g
of GSK-3 fusion protein (New England Biolabs) as a substrate, 200 M ATP
Experimental procedures in the reaction buffer (50 mM HEPES [pH 7], 2 mM MgCl2, 2 mM MnCl2, 200
mM Na3VO4, 200 mM NaF) for 30 min at 30C. Phosphorylation of the sub-
Cell culture and transfections strate was detected by Western blot with anti-GSK-3 serine 21/9 antibody.
Prostate carcinoma cell lines positive and null for PTEN (DU145 and PC3,
respectively) (ATCC) were cultured as suggested by ATCC. PC3 cells were Invasion and migration assay
transiently transfected with V5-tagged ILK dominant-negative (ILK-DN:V5), Invasion and migration was analyzed with a modified Boyden chamber assay
Empty vector, GFP-tagged PTEN (PTEN:GFP), HIF-1 dominant-negative, (cell culture inserts with a polycarbonate-filter [PVP, 8 m pore size; Corning
HIF-1 response element conjugated to GFP reporter (HRE:GFP), and/or Incorporated, New York] covered with growth factor reduced Matrigel [Bec-
Renilla for transfection control using 2–3 g of cDNA with 6 l of Lipofectin ton Dickinson, Massachusetts]). Two hundred microliters of cell suspension
reagent (Life Technologies Inc.), according to the manufacturer’s guidelines. (5  104 cells) were added to the upper wells and allowed to attach for 2
DU145 cells were transfected with 4 l of Fugene reagent (Roche Molecular hr at 37C. Increasing amounts of KP-392 and equivalent amounts of DMSO
Biochemicals). Intestinal epithelial cells (IEC-18) were stably transfected with diluted in 100 l were added to the upper well for a complete volume of
ILK wild-type (ILK-13 A1a3), ILK dominant-negative (ILK-DN GH31RH), or 300 l. The lower compartment was filled with F-12K medium containing 0
ILK antisense (ILK-14 antisense) (Hannigan et al., 1996). The parental IEC- or 20 ng/ml VEGF. Chambers were incubated for 16 hr in a 5% CO2, 99%
18 cells were used as the control. These cells were cultured as previously humidity, and 37C atmosphere. Cells on the under side of the filter were
described (Delcommenne et al., 1998). Human umbilical vein endothelial quantified by staining the cells with crystal violet, followed by counting the
cells (HUVEC) (ATCC) were cultured as suggested by ATCC. ILK-13 A1a3 number of cells per magnified field of view (6 fields/membrane).
and HUVEC cells were transfected with 6 l of Lipofectamine 2000 reagent
(Life Technologies Inc.) according to the manufacturer’s guidelines. Cell viability and proliferation assay
The metabolic activity of cells was determined in vitro using the colorimetric
Small interfering RNA (siRNA) cell proliferation/tetrazolium salt WST-1 reagent/Electro Coupling Solution
PC3 cells were transfected with small interfering RNA (siRNA) that specifically (WST-1/ECS) assay kit (Chemicon International, California) according to
targets the ILK gene (ILK-H or ILK-A) or nonsilencing control using 6 l of manufacturers instructions. The plate was incubated with the reagent for an
Lipofectin in OPTI-MEM (GibcoBRL) overnight. The cells were passaged 36 additional 30 min to 1 hr and quantified by spectrophotometry (OD 	 450
hr after incubation in complete media and harvested 36 to 48 hr later as nm). All experiments were performed in triplicate.
previously described (Troussard et al., 2003). siRNA duplexes were synthe-
sized by Xeragon Inc., MD. Sequences of the human ILK gene specifically Immunohistochemical staining
targeting the pH domain (ILK-H) (Troussard et al., 2003) and the integrin Tissues were frozen in compound-embedding medium (OCT; Miles Inc.,
binding domain (ILK-A) were chosen. The sequence of the DNA target of Indiana), and 10 m sections were collected on positively charged slides
ILK-A is 5
-GACGCTCAGCAGACATGTGGA-3
. A nonsilencing siRNA (16 (Wax-It Histology Services Inc., B.C., Canada). Sections were fixed with cold
base overlap with Thermotoga maritimia) was used as the control. acetone and blocked with 3% hydrogen peroxidase, followed by 1% bovine
serum albumin and normal rabbit serum. Sections were then incubated with
Chemical inhibitors the anti-mouse CD31 antibody (BD Pharmingen) overnight at 4C, followed
Cells were exposed to the highly specific small molecule inhibitor (KP-392; by incubation with a horseradish peroxidase conjugated anti-rat secondary
Kinetek Pharmaceuticals) (Cruet-Hennequart et al., 2003; Mills et al., 2003; antibody (Jackson Laboratories) for 1 hr at room temperature. The tissue
Tan et al., 2001, 2002; Persad et al., 2000, 2001a, 2001b) and equivalent was washed three times with PBS in between each step. The antibody
amounts of DMSO vehicle. PI-3 kinase inhibitor LY294002 (Calbiochem) localization was visualized with NOVARED substrate kit (Vector Laboratories,
and MEK1 inhibitor PD98059 (Cell Signaling Technology) were dissolved in California), used as directed by manufacturer, and the slides were counter-
stained with hematoxylin.DMSO as the vehicle.
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Endothelial tube formation assay
The endothelial tube formation assay was performed as previously described
Received: April 18, 2003with minor modification (Maeshima et al., 2000). A suspension of HUVEC in
Revised: September 18, 2003medium was seeded in triplicate into Matrigel-precoated 24-well plates in
the presence of 50 M KP-392. Published: December 22, 2003
Endothelial sprouting assay References
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seeded with HUVECs. Fibrin gels were made by dissolving 2.5 g/l bovine Attwell, S., Roskelley, C., and Dedhar, S. (2000). The integrin-linked kinase
fibrinogen (Sigma), 0.05 mg/ml Aprotinin (Sigma) in F-12K medium followed (ILK) suppresses anoikis. Oncogene 19, 3811–3815.
by passing the solution through a 0.22 m pore size filter to sterilize, and
Auerbach, R., Arensman, R., Kubai, L., and Folkman, J. (1975). Tumor-mixed with a fraction of HUVEC-coated bead. This mixture was transferred
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